Empowering Precision Diagnostics
Bringing ImmunoGuide ELISA technologies to Europe and beyond
Validated ELISA kits for therapeutic drug monitoring and anti-drug antibody detection, for clinical labs, research institutions, and biotech teams. For Research Use Only.
Featured ELISA kits
Drug-level and anti-drug antibody assays across TNF-alpha, VEGF, EGFR, HER2, and more.
ADALIMUMAB ELISA
Analyte: Adalimumab
View kitADALIMUMAB ELISA (MAB-BASED)
Analyte: Adalimumab
View kitAFLIBERCEPT ELISA
Analyte: Aflibercept
View kitANTIBODY TO ADALIMUMAB ELISA
Analyte: Adalimumab
View kitANTIBODY TO BEVACIZUMAB ELISA
Analyte: Bevacizumab
View kitANTIBODY TO CERTOLIZUMAB PEGOL ELISA
Analyte: Certolizumab Pegol
View kitFrom our journal
Background on ELISA methods, therapeutic drug monitoring, anti-drug antibodies, and assay validation.
Four Analytes, One Plasma Sample: The Assay Science Behind Multi-Biomarker Alzheimer's Testing
Four blood-based Alzheimer's disease biomarker tests were cleared by the FDA within fifteen months, and a five-analyte algorithmic panel is under 510(k) review. For immunoassay scientists deploying these panels, the analytical challenges of femtomolar sensitivity, cross-reactivity between tau isoforms, preanalytical instability of Aβ42, and cross-platform harmonization are the least-settled problems in making multi-biomarker results hold up outside a research cohort.
CPS1 Serum Immunoassay: What a Mitochondrial Enzyme Biomarker Tells You That ALT Cannot
Carbamoyl phosphate synthetase 1 (CPS1) is a hepatocyte-selective mitochondrial enzyme with a serum half-life of roughly 126 minutes, making it a near-real-time indicator of injury trajectory rather than injury presence. A 2026 Gut review synthesizes a decade of mechanistic and clinical work, including ELISA data from 764 serial samples across 270 acute liver failure patients, establishing CPS1 as a prognostically informative complement to standard aminotransferase panels. All AlpinaBioTech CPS1 immunoassay products are for Research Use Only.
Fortrea Acquires Worldwide Clinical Trials' Bioanalytical Lab: What the $45 Million CRO Deal Means for Assay Scientists
On September 2, 2026, Fortrea announced a $45 million all-cash acquisition of Worldwide Clinical Trials' Early Phase Services division, bringing a 60,000-square-foot GLP bioanalytical laboratory and a 200-bed GCP clinical pharmacology unit under one operational roof. For assay scientists running PK and immunogenicity programs, the deal changes the vendor map by eliminating inter-organization hand-offs between sample collection and bioanalytical processing. Broader CRO consolidation and pending FDA biosimilar guidance shifts make integrated bioanalytical infrastructure increasingly valuable for early-phase biologic programs.